Clinical Trial Search

Primary: The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism — 40; 6; 3; 46 Participants

Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min

Primary: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind) — 2; 0 Participants

Primary: Mean Blood Glucose Area Under the Curve (AUC 0-6h) — 2,096; 1,678 mmol*min/L

Primary: Accuracy of 18F-DOPA PET/CT Scans to Detect Focal Lesions in Children With Congenital Hyperinsulinism — 34; 10; 4; 52 cases

Primary: Median of Average Daily Percent Time Within a Glucose Target Range of 70-180 mg/dL (3.9-10 mmol/L) by CGM at Baseline (BL) and End of Treatment (EOT) — 81.7; 72.9; 83.4…

Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min

Primary: Neonatal Hypoglycemia — 3; 15 neonates

Primary: Mean Plasma Glucose Level. — 149.666118; 162.574753 mg/dL

Primary: Tolerability of Vitamin E Based on Responses to a Subject/Parent-reported Symptom Questionnaire After Vitamin E Supplementation Compared to Baseline — 2 Participants

Primary: Glucagon Response to Induced Hypoglycemia — 4.8; 8.8; 5.8; 4.2 pg/mL

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: LH — 7.7; 3.3; 7.9; 3.8 IU/L

Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale

Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL

Primary: Mean Intravenous Glucose Infusion Rate — 4.33; 9.51 mg/kg/minute — p=0.0037

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml

Primary: Area Under the Curve (AUC) Plasma Glucose — 26994.7; 32122.2 mg*min/dL

Primary: Glucose Disposal Rate (Rd)- the Rate of Glucose Infusion to Maintain Euglycemia During Steady State Insulin Infusion in mg/Min — 709; 429; 842; 497 mg/min — p=0.136

Primary: Insulin Secretion — 56766 pmol/l * 90 minutes

Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year

Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146

Primary: Linear Relationship Between HOMA-IR and Cognitive Function (R-squared) — 0.205; 0.299; 0.738; 0.0264 R-squared — p=0.162

Primary: [11C]5-hydroxy-tryptophan Uptake in the Pancreas — 0.17; 0.21; 0.20; 0.23 % of injected dose — p=0.5875

Primary: Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject — 3.8; -1.8; 7 mg/dL — p=0.000016

Primary: Myocardial Function: Left Ventricular Global Longitudinal Strain (%) — -16.8; -15.9 percentage of myocardial shortening — p=0.11

Primary: Mean Plasma Glucose Area Under the Curve (AUC 0-3h) — 22,192.5; 25,207.1; 21,715.9 mg*min/dl

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: Diurnal Level 2 Hypoglycemia Events (ADA, <54 mg/dL) as Measured by CGM in Patients With Severe Hyperinsulinemic Hypoglycemia (HH) — 5.2; 5.2; 2.7; 2.1 events per 14…